Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer
Recently updated guidelines for HR+/HER2- advanced or metastatic breast cancer include treatment recommendations for the use of inhibitors of CDK 4/6 and the PI3K/Akt/mTOR signal cascade. The emergence and approval of several CDK 4/6 inhibitors and everolimus, an mTOR inhibitor, warrant an assessment of new and emerging data to determine which agents should be used in specific patients with differing menopausal status and treatment outcomes goals.
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer will frame treatment decisions within the context of patient cases to facilitate care that is consistent with clinical guidelines and consensus recommendations. Guidance will also be provided to appropriately integrate PI3K/Akt/mTOR and CDK 4/6 targeted therapies into clinical practice for optimal personalized medicine for pre-, peri-, and post-menopausal HR+/HER2- breast cancer patients.
- Evaluate the updated clinical guidelines for combination therapies in the treatment of HR+/HER2- advanced breast cancer patients
- Integrate clinical data regarding the use of CDK 4/6 inhibitors and mTOR inhibitors to treat HR+/HER2- advanced breast cancer, including appropriate subpopulations
- Mitigate toxicities associated with multi-drug treatment regiments to improve patient outcomes
- Recognize potential drug-drug interactions to plan effective and safe treatment regimens for each patient
This activity is intended for community-based medical oncologists and other clinicians involved in the care of patients with advanced or metastatic breast cancer.
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Nurses: Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Physicians: The Potomac Center for Medical Education designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the CME accreditation of this program, please email: firstname.lastname@example.org.
Nurses: This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
For information about the CNE accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Jenny C. Chang, MD
Houston Methodist Cancer Center
Ruth O’Regan, MD
Professor of Medicine
University of Wisconsin School of Medicine and Public Health
Head, Hematololgy/Oncology Division
Associate Director of Clinical Research
Carbone Cancer Center
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control content of a continuing medical education program provided by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards of Commercial Support in advance of delivery of the activity to learners.
Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.). Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly provided by the Potomac Center for Medical Education and Rockpointe Oncology
Jointly provided by Global Education Group and Rockpointe Oncology
This activity is supported by education grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Utah Program Faculty
Reshma Mahtani, DO
Division of Hematology/Oncology
Sylvester Comprehensive Cancer Center
University of Miami Health System
Deerfield Beach, FL
Chicago Program Faculty
Gary I Cohen, MD, FACP, FASCO
Sandra and Malcolm Berman Cancer Institute
Greater Baltimore Medical Center
Johns Hopkins Oncology